Boehringer, Lilly start acute heart failure trial with JardianceBoehringer and Eli Lilly have started a large-scale trial of their diabetes drug Jardiance in acute heart failure, Share XBoehringer, Lilly start acute heart failure trial with Jardiancehttps://pharmaphorum.com/news/boehringer-lilly-start-acute-heart-failure-trial-with-jardiance/
Lilly and Boehringer rejig diabetes alliance as Jardiance soarsEli Lilly and Boehringer Ingelheim have changed the terms of their diabetes alliance to focus their energies on Share XLilly and Boehringer rejig diabetes alliance as Jardiance soarshttps://pharmaphorum.com/news/lilly-and-boehringer-rejig-diabetes-alliance-as-jardiance-soars/
Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritisBeating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting Share XNovartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritishttps://pharmaphorum.com/news/novartis-cosentyx-cant-exceed-humira-in-psoriatic-arthritis/
Lilly’s new drugs offset slumping sales of erectile dysfunction pill Cialis in Q3Eli Lilly upped its guidance for 2019 after posting strong third quarter results, as more recently released drugs Share XLilly’s new drugs offset slumping sales of erectile dysfunction pill Cialis in Q3https://pharmaphorum.com/news/lillys-new-drugs-offset-slumping-sales-of-erectile-dysfunction-drug-cialis-in-q3/
CHMP backs Lilly’s Baqsimi as non-injectable for severe low blood sugarThe EMA’s human medicines advisory committee has recommended approval of Eli Lilly’s Baqsimi as the first needle-free treatment Share XCHMP backs Lilly’s Baqsimi as non-injectable for severe low blood sugarhttps://pharmaphorum.com/news/chmp-backs-lillys-baqsimi-as-non-injectable-for-severe-low-blood-sugar/
Lilly’s $1.6bn cancer drug draws blank in pancreatic cancer trialEli Lilly is looking at other uses for its new cancer immunotherapy pegilodecakin after it flopped in a Share XLilly’s $1.6bn cancer drug draws blank in pancreatic cancer trialhttps://pharmaphorum.com/news/lillys-1-6bn-cancer-drug-draws-blank-in-pancreatic-cancer-trial/
FDA approves Lilly’s new migraine attack drug, rival from Allergan could followThe FDA has approved Eli Lilly’s new migraine drug lasmiditan, offering patients a new option to relieve symptoms Share XFDA approves Lilly’s new migraine attack drug, rival from Allergan could followhttps://pharmaphorum.com/news/fda-approves-lillys-new-migraine-attack-drug-rival-from-allergan-could-follow/
Humira tops list of drugs with unwarranted US price hikesAbbVie’s Humira heads a list of seven medicines that collectively contributed to a $5.1 billion increase in US Share XHumira tops list of drugs with unwarranted US price hikeshttps://pharmaphorum.com/news/humira-tops-list-of-drugs-with-unwarranted-us-price-hikes/
Xeris’ severe low blood sugar pen gets FDA approvalAfter 14 years of operations Xeris Pharma has its first-ever product approval, claiming an FDA okay for a Share XXeris’ severe low blood sugar pen gets FDA approvalhttps://pharmaphorum.com/news/xeris-severe-low-blood-sugar-pen-gets-fda-approval/
